Viral Destruction: Sponsored Q&A by Microthermics
A range of industries?biotechnology, food and pharmaceuticals?must keep viral contamination out of their products. To do this effectively, a company needs a reliable, continuous process, and one that can be scaled to the company?s specific needs. To explore these topics, BioPharm International talked with John Miles, PhD, president and founder of MicroThermics Inc. This company specializes in small-scale solutions in high-temperature short-time (HTST) and ultra-high temperature (UHT) processes.
A range of industries—biotechnology, food and pharmaceuticals—must keep viral contamination out of their products. To do this effectively, a company needs a reliable, continuous process, and one that can be scaled to the company’s specific needs. To explore these topics, BioPharm International talked with John Miles, PhD, president and founder of MicroThermics Inc. This company specializes in small-scale solutions in high-temperature short-time (HTST) and ultra-high temperature (UHT) processes.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
